Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials
Abstract Introduction Psoriasis is a chronic, inflammatory disease, which ranges in severity from mild to severe. Although topical therapies are frequently used to treat mild disease, they are not routinely used to treat patients with moderate-to-severe disease who have a larger proportion of their...
Saved in:
Main Authors: | Lars Iversen (Author), Merle Kurvits (Author), Anja Marieke Snel-Prentø (Author), Alan Menter (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
by: Anderko M, et al.
Published: (2019) -
New Calcipotriol/Betamethasone Dipropionate Foam Formulation for the Treatment of Psoriasis: An Overview
by: Tiago Torres, et al.
Published: (2018) -
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
by: Efstratios Vakirlis, et al.
Published: (2008) -
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
by: Pinter A, et al.
Published: (2018) -
Betamethasone dipropionate and calcipotriol foam as an adjuvant therapy in patients with severe psoriasis treated with biologic drugs
by: Michał Adamczyk, et al.
Published: (2024)